Clopidogrel may increase the anticoagulant activities of Fondaparinux. The metabolism of Clopidogrel can be decreased when combined with Paroxetine. The metabolism of Clotiazepam can be decreased when combined with Clopidogrel. The metabolism of Benzyl alcohol can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Astaxanthin. The metabolism of Domperidone can be decreased when combined with Clopidogrel. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Moclobemide resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Letaxaban. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Amlodipine. The metabolism of Dextromethorphan can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Theophylline. Ridogrel may increase the anticoagulant activities of Clopidogrel. Iloprost may increase the antiplatelet activities of Clopidogrel. The metabolism of Diclofenac can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be increased when combined with Fosphenytoin. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Pregabalin. The serum concentration of Clopidogrel can be decreased when it is combined with St. John's Wort. Clopidogrel may increase the anticoagulant activities of Triflusal. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Diflunisal. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimesulide. The metabolism of Pethidine can be decreased when combined with Clopidogrel. The serum concentration of Clopidogrel can be increased when it is combined with Aprepitant. The metabolism of Clopidogrel can be decreased when combined with Fosamprenavir. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Perhexiline. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Bepridil. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Prenylamine. The metabolism of Clopidogrel can be decreased when combined with Clemastine. Butylphthalide may increase the anticoagulant activities of Clopidogrel. Clopidogrel may increase the anticoagulant activities of Edoxaban. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Ticlopidine resulting in a loss in efficacy. The metabolism of clomethiazole can be decreased when combined with Clopidogrel. The serum concentration of Clopidogrel can be increased when it is combined with Fosaprepitant. The serum concentration of Clopidogrel can be decreased when it is combined with Lumacaftor. Clopidogrel may increase the anticoagulant activities of Pentaerythritol Tetranitrate. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Fendiline. The metabolism of Clopidogrel can be decreased when combined with Pyrimethamine. The metabolism of Clopidogrel can be decreased when combined with Topiroxostat. Clopidogrel may increase the anticoagulant activities of Certoparin. The metabolism of Ketobemidone can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Mibefradil. Clopidogrel may increase the anticoagulant activities of Argatroban. The metabolism of Methadone can be decreased when combined with Clopidogrel. The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clopidogrel. The serum concentration of Conivaptan can be increased when it is combined with Clopidogrel. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Eslicarbazepine acetate resulting in a loss in efficacy. The metabolism of Clopidogrel can be decreased when combined with Nefazodone. Clopidogrel may increase the anticoagulant activities of Ardeparin. The metabolism of Ixazomib can be decreased when combined with Clopidogrel. Dasatinib may increase the anticoagulant activities of Clopidogrel. Tesmilifene may increase the anticoagulant activities of Clopidogrel. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Tranylcypromine resulting in a loss in efficacy. Cangrelor may decrease the antiplatelet activities of Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Capecitabine. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Mesalazine. Trapidil may increase the anticoagulant activities of Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Cilnidipine. Clopidogrel may increase the anticoagulant activities of Ozagrel. The metabolism of Diazepam can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Telithromycin. The serum concentration of Clopidogrel can be decreased when it is combined with Cyproterone acetate. Clopidogrel may increase the anticoagulant activities of Parnaparin. The serum concentration of Amodiaquine can be increased when it is combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Gabapentin. The serum concentration of Rosuvastatin can be increased when it is combined with Clopidogrel. The risk or severity of adverse effects can be increased when Limaprost is combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Irbesartan. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lercanidipine. The metabolism of Clopidogrel can be decreased when combined with Ropinirole. Clopidogrel may increase the anticoagulant activities of Fondaparinux sodium. Clopidogrel may increase the anticoagulant activities of Danaparoid. Clopidogrel may increase the anticoagulant activities of Fluindione. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Sertraline resulting in a loss in efficacy. Clopidogrel may increase the anticoagulant activities of Ditazole. Clopidogrel may increase the anticoagulant activities of Rivaroxaban. The serum concentration of Clopidogrel can be decreased when it is combined with Teriflunomide. The metabolism of Ropivacaine can be decreased when combined with Clopidogrel. The risk or severity of adverse effects can be increased when Clopidogrel is combined with Apixaban. Clopidogrel may increase the anticoagulant activities of Anistreplase. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Etravirine resulting in a loss in efficacy. The metabolism of Tretinoin can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Efonidipine. Clopidogrel may increase the anticoagulant activities of Nafamostat. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nifedipine. Pentoxifylline may increase the antiplatelet activities of Clopidogrel. The metabolism of Ethylmorphine can be decreased when combined with Clopidogrel. Clopidogrel may increase the anticoagulant activities of Troxerutin. The risk or severity of adverse effects can be increased when Rifampicin is combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Tenofovir disoproxil. Clopidogrel may increase the anticoagulant activities of Gabexate. The metabolism of Clopidogrel can be decreased when combined with Dosulepin. The metabolism of Clopidogrel can be decreased when combined with Boceprevir. Clopidogrel may increase the anticoagulant activities of Reviparin. Clopidogrel may increase the anticoagulant activities of Streptokinase. Treprostinil may increase the antiplatelet activities of Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Leflunomide. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Ketoconazole resulting in a loss in efficacy. The serum concentration of Clopidogrel can be decreased when it is combined with Mitotane. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Pinaverium. Ketanserin may increase the anticoagulant activities of Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Risedronate. The metabolism of Clopidogrel can be decreased when combined with Atomoxetine. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Azimilide. Ifetroban may increase the anticoagulant activities of Clopidogrel. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Efavirenz resulting in a loss in efficacy. The metabolism of Clopidogrel can be decreased when combined with Posaconazole. The serum concentration of Clopidogrel can be increased when it is combined with Quazepam. The metabolism of Clopidogrel can be decreased when combined with Dihydroergotamine. Clopidogrel may increase the anticoagulant activities of Enoxaparin. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Ziconotide. The metabolism of Clopidogrel can be decreased when combined with Floxuridine. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Fluoxetine resulting in a loss in efficacy. The metabolism of Clopidogrel can be decreased when combined with Lopinavir. The metabolism of Loperamide can be decreased when combined with Clopidogrel. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Barnidipine. The metabolism of Clopidogrel can be decreased when combined with Trimethoprim. The metabolism of Clopidogrel can be decreased when combined with Crisaborole. The metabolism of Clopidogrel can be decreased when combined with Azithromycin. Clopidogrel may increase the anticoagulant activities of Protein S human. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tranilast. Clopidogrel may increase the anticoagulant activities of Vorapaxar. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nisoldipine. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Gemfibrozil resulting in a loss in efficacy. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Armodafinil resulting in a loss in efficacy. The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Clotrimazole resulting in a loss in efficacy. The metabolism of Brivaracetam can be decreased when combined with Clopidogrel. The metabolism of Clopidogrel can be decreased when combined with Lovastatin. The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimodipine. The serum concentration of Clopidogrel can be increased when it is combined with Vemurafenib. The metabolism of Tamoxifen can be decreased when combined with Clopidogrel. The metabolism of Seratrodast can be decreased when combined with Clopidogrel.